Yan Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yan Li has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Junling Li
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
11 shared publications - Puyuan Xing
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
11 shared publications - Jianming Ying
Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
10 shared publications - Shouzheng Wang
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P.R. China
10 shared publications - Tongji Xie
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P.R. China
10 shared publications - Fei Teng
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P.R. China
9 shared publications
Latest Publications
- 20 October 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
Firmonertinib 160 mg in EGFR-mutated non-small cell lung cancer with brain metastases after EGFR-tyrosine kinase inhibitor resistance (iFORCE): Clinical outcomes and mechanistic insights
Background: Brain metastases (BM) are frequent in EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC) and remain challenging after prior EGFR tyrosine kinase inhibitor (TKI) therapy. This exploratory study evaluated high-dose firmonertinib and explored subtype-specific spatial biology. Methods: iFORCE was a prospective, single-center, single-arm study. Eligible patients had advanced NSCLC harboring EGFR mutations with previously treated BM following EGFR-TKI therapy, or intracranial disease progression. Patients received 160 mg firmonertinib once daily. The primary endpoint was intracranial progression-free survival (iPFS). Archival paired primary tumors and BM specimens from an independent retrospective cohort underwent exploratory digital spatial profiling (DSP). Results: Twenty-three patients were enrolled. At a median follow-up of 19.7 months (95% CI, 14.5-5.3), median iPFS was 14.6 months (95% CI, 4.2-not estimable [NE]), with 12- and 18-month iPFS rates of 53.8% and 46.1%, respectively. Based on the best intracranial overall response, intracranial objective response and disease control rates were 34.8% (95% CI, 16.4-57.3) and 91.3% (95% CI, 72.0-98.9). Median systemic PFS was 10.7 months (95% CI, 3.9-NE). Treatment-related adverse events occurred in 13 (56.5%) patients, mostly grade 1; 1 patient (4.3%) developed grade 3 stomatitis. No treatment discontinuations or treatment-related deaths were observed. DSP revealed distinct EGFR subtype-specific BM ecosystems: exon 19 deletion tumors retained immune-enriched inflammatory programs, whereas L858R-mutated tumors showed tumor-intrinsic cell-cycle, DNA-repair, RNA-splicing, apoptosis-resistance, and immune-evasion features. Conclusions: Firmonertinib 160 mg showed promising intracranial activity with a manageable safety profile in EGFR-TKI-treated EGFRm NSCLC with BM. L858R BM displayed tumor-intrinsic, microenvironment-independent biology, suggesting preferential sensitivity to high-dose firmonertinib.
- 20 October 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
Firmonertinib 160 mg in EGFR-mutated non-small cell lung cancer with brain metastases after EGFR-tyrosine kinase inhibitor resistance (iFORCE): Clinical outcomes and mechanistic insights
Background: Brain metastases (BM) are frequent in EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC) and remain challenging after prior EGFR tyrosine kinase inhibitor (TKI) therapy. This exploratory study evaluated high-dose firmonertinib and explored subtype-specific spatial biology. Methods: iFORCE was a prospective, single-center, single-arm study. Eligible patients had advanced NSCLC harboring EGFR mutations with previously treated BM following EGFR-TKI therapy, or intracranial disease progression. Patients received 160 mg firmonertinib once daily. The primary endpoint was intracranial progression-free survival (iPFS). Archival paired primary tumors and BM specimens from an independent retrospective cohort underwent exploratory digital spatial profiling (DSP). Results: Twenty-three patients were enrolled. At a median follow-up of 19.7 months (95% CI, 14.5-5.3), median iPFS was 14.6 months (95% CI, 4.2-not estimable [NE]), with 12- and 18-month iPFS rates of 53.8% and 46.1%, respectively. Based on the best intracranial overall response, intracranial objective response and disease control rates were 34.8% (95% CI, 16.4-57.3) and 91.3% (95% CI, 72.0-98.9). Median systemic PFS was 10.7 months (95% CI, 3.9-NE). Treatment-related adverse events occurred in 13 (56.5%) patients, mostly grade 1; 1 patient (4.3%) developed grade 3 stomatitis. No treatment discontinuations or treatment-related deaths were observed. DSP revealed distinct EGFR subtype-specific BM ecosystems: exon 19 deletion tumors retained immune-enriched inflammatory programs, whereas L858R-mutated tumors showed tumor-intrinsic cell-cycle, DNA-repair, RNA-splicing, apoptosis-resistance, and immune-evasion features. Conclusions: Firmonertinib 160 mg showed promising intracranial activity with a manageable safety profile in EGFR-TKI-treated EGFRm NSCLC with BM. L858R BM displayed tumor-intrinsic, microenvironment-independent biology, suggesting preferential sensitivity to high-dose firmonertinib.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S1 from Evolutionary Characteristics and Immunologic Divergence of Lung and Brain Metastasis Lesions in NSCLC
The TMB distribution of all primary and metastases samples. The total TMB (defined as the number of nonsynonymous mutations) in each group.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Evolutionary Characteristics and Immunologic Divergence of Lung and Brain Metastasis Lesions in NSCLC
The TMB distribution of all primary and metastases samples. The total TMB (defined as the number of nonsynonymous mutations) in each group.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Evolutionary Characteristics and Immunologic Divergence of Lung and Brain Metastasis Lesions in NSCLC
Brain metastases (BM) is one of the main reasons for lung cancer-related deaths but lack prediction methods. Many patients with BMs do not benefit from immunotherapy. A comprehensive genomic analysis of matched primary tumors (PT) and their BM lesions may provide new insight into the evolutionary and immune characteristics. To describe evolutionary features and immune characteristic differences, we analyzed whole-exome sequencing data for 28 paired PT and BM samples from 14 patients with non-small cell lung cancer. In addition, we used another 26 matched PT and BM samples as a validation cohort. We found that total mutational signatures were relatively consistent between paired primary and brain metastatic tumors. Nevertheless, the shared mutations of the two lesions were fewer than the mutations present in each of the lesions alone. In the process of BM, driver genes undergo evolutionary branches. Typical driver genes, including EGFR and TP53, appear relatively conserved throughout evolution; however, specific signals are enriched in BM lesions. We found several main characteristics of lung cancer BMs that were different from primary lung cancer, such as genomic instability, novel driver genes, tumor mutation burden, and BM lesion private neoantigens. In addition, the estimated timing of dissemination showed that BMs might occur early in lung cancer.Implications:Mechanistic insight from this study provides new insight into the biology of the metastatic brain process and a new beneficial approach for preventing and treating lung cancer BMs.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Evolutionary Characteristics and Immunologic Divergence of Lung and Brain Metastasis Lesions in NSCLC
Brain metastases (BM) is one of the main reasons for lung cancer-related deaths but lack prediction methods. Many patients with BMs do not benefit from immunotherapy. A comprehensive genomic analysis of matched primary tumors (PT) and their BM lesions may provide new insight into the evolutionary and immune characteristics. To describe evolutionary features and immune characteristic differences, we analyzed whole-exome sequencing data for 28 paired PT and BM samples from 14 patients with non-small cell lung cancer. In addition, we used another 26 matched PT and BM samples as a validation cohort. We found that total mutational signatures were relatively consistent between paired primary and brain metastatic tumors. Nevertheless, the shared mutations of the two lesions were fewer than the mutations present in each of the lesions alone. In the process of BM, driver genes undergo evolutionary branches. Typical driver genes, including EGFR and TP53, appear relatively conserved throughout evolution; however, specific signals are enriched in BM lesions. We found several main characteristics of lung cancer BMs that were different from primary lung cancer, such as genomic instability, novel driver genes, tumor mutation burden, and BM lesion private neoantigens. In addition, the estimated timing of dissemination showed that BMs might occur early in lung cancer.Implications:Mechanistic insight from this study provides new insight into the biology of the metastatic brain process and a new beneficial approach for preventing and treating lung cancer BMs.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Table S1 from Evolutionary Characteristics and Immunologic Divergence of Lung and Brain Metastasis Lesions in NSCLC
The basic clinical information of all patients.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Evolutionary Characteristics and Immunologic Divergence of Lung and Brain Metastasis Lesions in NSCLC
The basic clinical information of all patients.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure Legends from Evolutionary Characteristics and Immunologic Divergence of Lung and Brain Metastasis Lesions in NSCLC
Supplementary Figure 1. The TMB distribution of all primary and metastases samples. The total TMB (defined as the number of nonsynonymous mutations) in each group.Supplementary Table 1. The basic clinical information of all patients.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure Legends from Evolutionary Characteristics and Immunologic Divergence of Lung and Brain Metastasis Lesions in NSCLC
Supplementary Figure 1. The TMB distribution of all primary and metastases samples. The total TMB (defined as the number of nonsynonymous mutations) in each group.Supplementary Table 1. The basic clinical information of all patients.
- Open Access
- 19 December 2022
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 21 (4) , 374-385
Evolutionary Characteristics and Immunologic Divergence of Lung and Brain Metastasis Lesions in NSCLC
Brain metastases (BM) is one of the main reasons for lung cancer-related deaths but lack prediction methods. Many patients with BMs do not benefit from immunotherapy. A comprehensive genomic analysis of matched primary tumors (PT) and their BM lesions may provide new insight into the evolutionary and immune characteristics. To describe evolutionary features and immune characteristic differences, we analyzed whole-exome sequencing data for 28 paired PT and BM samples from 14 patients with non-small cell lung cancer. In addition, we used another 26 matched PT and BM samples as a validation cohort. We found that total mutational signatures were relatively consistent between paired primary and brain metastatic tumors. Nevertheless, the shared mutations of the two lesions were fewer than the mutations present in each of the lesions alone. In the process of BM, driver genes undergo evolutionary branches. Typical driver genes, including EGFR and TP53, appear relatively conserved throughout evolution; however, specific signals are enriched in BM lesions. We found several main characteristics of lung cancer BMs that were different from primary lung cancer, such as genomic instability, novel driver genes, tumor mutation burden, and BM lesion private neoantigens. In addition, the estimated timing of dissemination showed that BMs might occur early in lung cancer. Implications: Mechanistic insight from this study provides new insight into the biology of the metastatic brain process and a new beneficial approach for preventing and treating lung cancer BMs.
- 19 December 2022
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 21 (4) , 374-385
Open AccessEvolutionary Characteristics and Immunologic Divergence of Lung and Brain Metastasis Lesions in NSCLC
Brain metastases (BM) is one of the main reasons for lung cancer-related deaths but lack prediction methods. Many patients with BMs do not benefit from immunotherapy. A comprehensive genomic analysis of matched primary tumors (PT) and their BM lesions may provide new insight into the evolutionary and immune characteristics. To describe evolutionary features and immune characteristic differences, we analyzed whole-exome sequencing data for 28 paired PT and BM samples from 14 patients with non-small cell lung cancer. In addition, we used another 26 matched PT and BM samples as a validation cohort. We found that total mutational signatures were relatively consistent between paired primary and brain metastatic tumors. Nevertheless, the shared mutations of the two lesions were fewer than the mutations present in each of the lesions alone. In the process of BM, driver genes undergo evolutionary branches. Typical driver genes, including EGFR and TP53, appear relatively conserved throughout evolution; however, specific signals are enriched in BM lesions. We found several main characteristics of lung cancer BMs that were different from primary lung cancer, such as genomic instability, novel driver genes, tumor mutation burden, and BM lesion private neoantigens. In addition, the estimated timing of dissemination showed that BMs might occur early in lung cancer. Implications: Mechanistic insight from this study provides new insight into the biology of the metastatic brain process and a new beneficial approach for preventing and treating lung cancer BMs.